A long story made too short: surrogate variables and the communication of HPV vaccine trial results

Gerhardus A, Razum O (2010)
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH 64(5): 377-378.

Journal Article | Published | English

No fulltext has been uploaded

Author
;
Publishing Year
ISSN
PUB-ID

Cite this

Gerhardus A, Razum O. A long story made too short: surrogate variables and the communication of HPV vaccine trial results. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH. 2010;64(5):377-378.
Gerhardus, A., & Razum, O. (2010). A long story made too short: surrogate variables and the communication of HPV vaccine trial results. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 64(5), 377-378.
Gerhardus, A., and Razum, O. (2010). A long story made too short: surrogate variables and the communication of HPV vaccine trial results. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH 64, 377-378.
Gerhardus, A., & Razum, O., 2010. A long story made too short: surrogate variables and the communication of HPV vaccine trial results. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 64(5), p 377-378.
A. Gerhardus and O. Razum, “A long story made too short: surrogate variables and the communication of HPV vaccine trial results”, JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, vol. 64, 2010, pp. 377-378.
Gerhardus, A., Razum, O.: A long story made too short: surrogate variables and the communication of HPV vaccine trial results. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH. 64, 377-378 (2010).
Gerhardus, Ansgar, and Razum, Oliver. “A long story made too short: surrogate variables and the communication of HPV vaccine trial results”. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH 64.5 (2010): 377-378.
This data publication is cited in the following publications:
This publication cites the following data publications:

8 Citations in Europe PMC

Data provided by Europe PubMed Central.

A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
Guerrero AM, Genuino AJ, Santillan M, Praditsitthikorn N, Chantarastapornchit V, Teerawattananon Y, Alejandria M, Toral JA., BMC Public Health 15(), 2015
PMID: 26223975
Ethical considerations in post-market-approval monitoring and regulation of vaccines.
Thompson A, Komparic A, Smith MJ., Vaccine 32(52), 2014
PMID: 25454882
On the relationship between human papilloma virus vaccine and autoimmune diseases.
Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, Gentili M, Brusadelli T, Clementi E, Radice S., Autoimmun Rev 13(7), 2014
PMID: 24468416
Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants.
Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y., Am. J. Reprod. Immunol. 70(4), 2013
PMID: 23902317
Who profits from uncritical acceptance of biased estimates of vaccine efficacy and safety?
Tomljenovic L, Shaw CA., Am J Public Health 102(9), 2012
PMID: 22813421
No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil?
Tomljenovic L, Shaw CA., J. Intern. Med. 272(5), 2012
PMID: 22540172
[Do media reports and public brochures facilitate informed decision making about cervical cancer prevention?].
Neumeyer-Gromen A, Bodemer N, Muller SM, Gigerenzer G., Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 54(11), 2011
PMID: 22015792
Human papillomavirus vaccination in Africa.
Ouedraogo N, Muller O, Jahn A, Gerhardus A., Lancet 378(9788), 2011
PMID: 21784261

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 20445208
PubMed | Europe PMC

Search this title in

Google Scholar